
|Articles|April 24, 2004
Genentech enrolling patients for Lucentis clinical trial
Genentech, South San Francisco, CA, announced that the biotechnologycompany is enrolling patients into a Phase III clinical trial for its age-relatedmacular degeneration (AMD) drug Lucentis (ranibizumab, rhuFab V2).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement


















